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Background: Roughly 30% of schizophrenia patients fail to respond to at least two 
antipsychotic trials. Psychosis has been traditionally considered to be poorly sensitive to 
psychotherapy. Nevertheless, there is increasing evidence that psychological interventions 
could be considered in treatment-resistant psychosis (TRP). Despite the relevance of the 
issue and the emerging neurobiological underpinnings, no systematic reviews have been 
published. Here, we show a systematic review of psychotherapy interventions in TRP 
patients of the last 25 years.
Methods: The MEDLINE/PubMed, ISI WEB of Knowledge, and Scopus databases were 
inquired from January 1, 1993, to August 1, 2018, for reports documenting augmentation 
or substitution with psychotherapy for treatment-resistant schizophrenia (TRS) and TRP 
patients. Quantitative data fetched by Randomized Controlled Trials (RCTs) were pooled 
for explorative meta-analysis.
Results: Forty-two articles have been found. Cognitive behavioral therapy (CBT) was 
the most frequently recommended psychotherapy intervention for TRS (studies, n = 
32, 76.2%), showing efficacy for general psychopathology and positive symptoms as 
documented by most of the studies, but with uncertain efficacy on negative symptoms. 
Other interventions showed similar results. The usefulness of group therapy was supported 
by the obtained evidence. Few studies focused on negative symptoms. Promising results 
were also reported for resistant early psychosis.
Limitations: Measurement and publication bias due to the intrinsic limitations of the 
appraised original studies.
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Conclusions: CBT, psychosocial intervention, supportive counseling, psychodynamic 
psychotherapy, and other psychological interventions can be recommended for clinical 
practice. More studies are needed, especially for non-CBT interventions and for all 
psychotherapies on negative symptoms.
Keywords: treatment-resistant psychosis, dopamine supersensitivity, negative symptoms, psychotherapy, 
behavioral therapy, group psychotherapy, positive symptoms
INTRODUCTION
Schizophrenia affects approximately 1% of the population, usually 
starting in adolescence or young adulthood, frequently leading 
to persistent disability, with a high risk of suicide (8%). Despite 
the advance in antipsychotics treatment, approximately 30% of 
patients with schizophrenia show a poor response or no response 
to antipsychotics (1–7), demonstrating persistent positive 
symptoms (i.e., hallucinations, delusions). The experience of 
persistent delusions and hallucinations may result in further 
disability, poor prognosis, and risk of suicide (8, 9). Finally, 
treatment-resistant psychosis (TRP) is responsible for increasing 
health assistance expenditure. For instance, in the United 
States, treatment-resistant schizophrenia (TRS) adds more than 
34 billion dollars in the annual direct medical costs (10).
In the presence of pharmacological treatment resistance, 
can nonpharmacological, psychotherapy-based interventions 
significantly overcome the therapeutic response deadlock? 
Which psychotherapy in combination with antipsychotics does 
work better? Finally, what are the limitations and the pitfalls of 
the research on psychotherapy in TRS and TRP?
This review aims to provide a critical, systematic overview 
covering the last 25 years of published results of all types of 
psychotherapy, as adjunctive or substitutive therapy, specifically in 
TRS or TRP patients, including early psychosis and psychotic onset. 
TRS and TRP for many patients are lifelong mental disorders with 
significant consequences on most functional domains (11,  12). 
TRS represents a severe condition with relevant clinical, social, and 
health costs and consequences (2). In clinical practice, the criteria 
to define TRS have not been always consistent over time (2). The 
first complete definition was introduced in the seminal article of 
Kane and collaborators (13) on clozapine efficacy in TRS. Most of 
the new proposed criteria require the lack of response to at least 
two consecutive treatments with antipsychotics; in most cases, one 
of the two antipsychotics should be an atypical one, of adequate 
dose and duration (≥6 weeks). An adequate dose of antipsychotic 
medication in the most recent report is defined as a daily dose 
of ≥400 mg chlorpromazine equivalence (14–17). The lack of 
response has been indicated as a relative change in the evaluation 
scales (i.e., ≥20% decrease in the Positive and Negative Syndrome 
Scale) (17). Psychotic symptom persistence has been demonstrated 
to cause distress and serious interference with functioning (18), 
complicating the clinical course of schizophrenia. Therefore, a large 
proportion of patients may never reach a functional recovery (19). 
These patients show poor global functioning and life quality (20, 
21), increased drug abuse (6), and reduced cognitive performance 
compared to patients who respond to the treatment  (22). 
Persistent psychotic symptoms have been observed for 2 years 
after the initiation of symptoms in 15% of cases (23). In a 15-year 
follow-up study of patients affected by nonaffective psychosis, 
every psychotic episode has resulted in raising the probability to 
experience residual positive symptoms. At least 25% of patients 
showed persistent positive and negative symptoms after the first 
episode, while nearly 50% presented persistent symptoms after the 
fourth episode (24). According to this progression of symptoms 
persistence, the total number of treatment-resistant patients can 
increase up to 60% (25). Two forms of treatment resistance have 
been hypothesized: a type of resistance that is already present at 
the onset of the pathology, and a second one that develops later 
on during the trajectory of the disorder and after a period of 
successful response to antipsychotics (26–28). Remarkably, 82% 
of TRS had been reported to be resistant since their first episode 
of psychosis, while 18% of patients with TRS develop resistance 
after a period of adequate response. It has been reported that 
the first group could recognize a neurodevelopmental disorder 
with relatively normal dopaminergic function and prevalent 
aberrant cortical–subcortical dysfunction (29, 30). Clozapine, 
the prototypical second-generation antipsychotic, is considered 
the gold standard of pharmacological treatment for TRS (31–34), 
even if its superiority in comparison to other second-generation 
antipsychotics has been challenged in recent meta-analysis (16, 
35, 36). Moreover, drug combinations strategies are often used 
in TRP (32, 37–39) and in the “ultraresistant patients,” who do 
not respond or respond only partially to clozapine. It has been 
estimated that approximately 30% of patients who are treated 
with clozapine do not respond adequately (14, 40, 41). Clinical 
features at diagnosis can only partially predict resistance to the 
treatment: poorer premorbid functions, an earlier age at onset 
of positive symptoms, family history of schizophrenia spectrum 
disorder, longer duration of untreated psychosis (DUP) (26, 
42–48), male gender, a history of specific substance abuse, severe 
negative symptoms, and presence of soft neurological signs (3, 
23, 42, 47, 49–51). Functional and structural brain imaging has 
identified potential brain abnormalities related to treatment 
response or resistance, specifically at the level of the frontal 
cortex, basal ganglia, corpus callosum, and anterior cingulate. 
Nevertheless, correlations with brain abnormalities have still 
not been consistently replicated (52, 53). In our study, we 
included an exploratory meta-analysis to provide a quantitative 
synthesis of data from Randomized Controlled Trials (RCTs). 
The aim of this latter analysis was to compare the efficacy of an 
augmentation approach with cognitive behavioral therapy (CBT) 
versus  treatment as usual (TAU) in patients with treatment-
resistant schizophrenia.
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Psychotherapy Approach to Psychosis
The so-called “Dodo Bird Verdict” has been suggested in many 
reports to indicate that different psychological therapies are of 
nonspecific or similar efficacy, but this view is controversial and can 
be contrasted by meta-analytic studies (54–59). Criteria to define 
evidence-based psychotherapy (EBP) have been established in 
youth psychotherapy (60). The comparison between EBP and the 
usual care has shown a more effective performance in the former 
but advantages in the latter (61, 62). Some researchers have used 
befriending (BF), an atheoretical and manualized control therapy 
(63), as a nonspecific relationship that works as a control group, 
but it has been shown that this approach could have a therapeutic 
impact, too (64). Nevertheless, psychological interventions have 
become more widely accepted over the past two decades (65–67). 
The majority of recent publications consider CBT the elective 
psychotherapy for psychosis (68, 70) and other treatments are 
not frequently studied. In particular, the number of articles on 
the psychodynamic treatment of schizophrenia was very high 
from 1966 to 1987, with the decline starting after 1980; however, 
no one was centered on treatment-resistant schizophrenia (71). 
Mueser et al. observed that the published studies are “only a 
crude index of the current therapy in schizophrenia since a 
small fraction of psychodynamic psychotherapy practitioners 
publishes their treatment cases.” In the history of psychodynamic 
psychiatry and psychoanalysis, psychosis has been traditionally 
considered impervious to treatment. However, recent literature 
points out to the association between environmental factors, 
such as childhood adversity, and the development of psychotic 
experiences, psychotic symptoms, and diseases (72–79). In fact, 
trajectory-based approaches to study clinical consequences to 
potentially traumatic events (PTEs) have recently emerged. 
In particular, prototypical trajectories have been found across 
independent studies, and resilience seems to determine the 
modal response to adversity (80). Abnormal early-life experience, 
such as early relationships characterized by a “lack of affectivity” 
during the first year of life, has been suggested to be potentially 
pathogenic (81). This aspect should also be evaluated as 
psychologically determinant in contributing to the development 
of a psychotic disorder. Furthermore, recent literature has also 
shown the important role played by the therapeutic relationships 
in all psychiatric settings in predicting the outcome (82–84). It 
has also been evidenced how therapist attitude and characteristics 
in the relationship can influence the outcome specifically in TRS 
patients (85).
Therefore, in the last 20 years, there has been a growing 
interest in developing a psychological intervention for people 
who continue to experience psychotic symptoms despite 
adequate pharmacological treatment (14, 86–90). In early 
interventions on psychosis, psychotherapy is a potentially 
relevant part of the treatment, whereas the medication 
only might neither be sufficient nor efficient (44, 91–96). 
Medications can also determine a worse clinical condition and 
be detrimental, since they can have brain structural effects (97–
99). Remarkably, antipsychotic treatment can result in further 
psychotic symptomatology at this stage, due to a dopaminergic 
supersensitivity effect, induced by the treatment itself (100–102). 
It  has been observed that early psychosis patients may present 
treatment resistance. In particular, approximately 20% continue 
to have significant residual positive symptoms after 12 weeks of 
comprehensive treatment (103). Nevertheless, in early psychosis, 
a psychological or an integrated therapy with an adequate dose 
of medication could be effective, maximize results, prevent 
relapses, achieve recovery, and overcome drug resistance. Studies 
on the prodromal phase of psychosis have demonstrated that 
psychological treatments can be effective in reducing transition 
to psychosis (103, 104). Also, studies on psychosis onset have 
shown that, in selected cases, psychological interventions can be 
more appropriated as the first choice than medications (86, 105–
107). The National Institute for Clinical Excellence (NICE) (108) 
and the Schizophrenia Patient Outcome Report Team (PORT) 
guidance included cognitive behavioral therapy (CBT) in their 
preferred list of treatments for schizophrenia (108, 109).
MATERIALS AND METHODS
Aimed at achieving a high standard of reporting, we followed 
the procedures indicated by the 2009 update of the Preferred 
Reporting Items for Systematic reviews and Meta-Analyses 
(PRISMA) guidelines (http://www.prisma-statement.org/) (see 
Figure 1) (110).
Eligibility Criteria, Information Sources, 
and Search Strategy
We limited our search to those records related to TRP, TRS 
and psychotherapy of the last 25 years, from January 1, 1993, 
until August 1, 2018. Such timeframe owed to methodological 
considerations aimed at including studies relying on homogeneous 
diagnostic criteria. A systematic database search was performed 
on MEDLINE/PubMed, Web of Science/ISI Web of Knowledge, 
and Scopus. The following combinations of keywords have been 
used: “treatment resistant psychosis OR treatment resistance 
psychosis AND treatment-resistant schizophrenia OR treatment 
resistance schizophrenia AND psychotherapy,” “antipsychotic 
resistant response OR antipsychotic resistance response AND 
psychotherapy,” “clozapine resistance AND psychotherapy OR 
augmentation strategies,” “partial responders antipsychotics AND 
psychotherapy OR augmentation psychotherapy,” “clozapine 
non responders AND/OR poor responder antipsychotics AND 
psychotherapy OR augmentation psychotherapy,” “psychosis 
AND antipsychotics psychotherapy augmentation,” “medical 
resistance AND psychosis psychotherapy,” “treatment resistant 
OR treatment-resistant OR treatment resistance OR treatment-
resistance AND psychosis AND/OR schizophrenia AND 
psychotherapy AND/OR psychodynamic psychotherapy AND/
OR therapeutic relationship.” RCT, meta-analyses relevant open-
label trials, significant articles, including case reports, controlled 
and uncontrolled trials, and ongoing trials of pharmacological 
treatments, augmented or substituted with psychotherapeutic 
approaches to TRP and TRS, have been selected. No language 
restriction was applied, and relevant cross-references were 
retrieved as necessary. Studies  concerning augmentation or 
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substitution with medication have been excluded. Articles 
referring to TR in different pathologies from nonaffective psychosis 
and schizophrenia spectrum disorders have also been excluded. 
To overcome the problem of nonspecificity in psychotherapy, 
particular attention has been paid to the psychotherapy method 
and its details and to the control groups. Critical and systematic 
reviews on psychological interventions in TRP and TRS have been 
considered for a further review of literature. The most frequent 
cluster of symptoms measured by clinical scale assessments that 
have been included are 1) general psychopathology, 2) positive 
and negative symptoms, 3) cognitive symptoms, 4) affective 
symptoms, and 5) social functioning. The following aspects have 
been considered: 1) the stage of illness, such as the prodromal 
phase, the onset, any time after the onset and during the chronic 
phase; 2) the population of patients regarding diagnosis, duration 
of illness, age, age of onset, and duration of untreated psychosis 
(DUP); and 3) the type of psychotherapy, such as individual 
or group, duration of the treatment, frequency and time of the 
sessions, type of comparison or control group (if present), and 
blindness of the raters.
About the meta-analysis portion, we performed a fixed-effect 
meta-analysis aimed at evaluating the efficacy of augmentation 
therapy with CBT on the positive symptoms of Positive and 
Negative Syndrome Scale (PANSS) (see Figure 2). The same 
analysis was replicated on the negative symptoms of PANSS (see 
Figure 3). A further meta-analytical random-effect evaluation 
was carried out in order to evaluate the effectiveness of 
augmentation therapy with CBT in terms of variation of the total 
PANSS scores (see Figure 4). The estimate uses SMD (standard 
mean difference pre- vs. posttreatment) as an effect size.
The heterogeneity index of the studies and the publication 
bias were respectively evaluated with I2 and Funnel plots (see 
Figures 5, 6, and 7).
The inclusion criteria used for the selection of the RCTs 
suitable for the meta-analysis carried out were as follows:
1. Presence of a uniform control group (patients treated with the 
usual therapy) (TAU)
2. Measurement of outcome with validated scales (PANSS)
3. Studies only of the RCT type
4. Same type of psychotherapeutic intervention (individual CBT)
5. Evaluation, pre- and posttreatment, with the same type of scale
6. Follow-up to 6 or 9 months
Study Selection
Included papers were those reporting efficacy outcomes about the 
positive and/or negative symptoms of TRS and TRP exposed to 
antipsychotic replacement or augmentative psychotherapy, any 
modality. Outcome measures could be reordered by means of 
varying standard rating tools or by means of the clinicians’ judgment.
FIGURE 1 | Flow chart of review procedures.
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Data Collection Process
Two authors (DP and MP) conducted a two-step literature 
search, examining all titles and abstracts, accessing the full 
texts of potentially relevant papers. Upon data collection and 
extraction, the appointed authors compared their results with 
each other to reach a final consensus based on consensual 
inclusion and exclusion criteria. Any eventual discrepancy 
between the principal investigators, blind to each other, was 
solved by consultation with the senior author (AdB). Finally, 
the leading senior author with considerable experience on the 
topic (AdB) assisted in manuscript revision. Data were sought 
for the following characteristics: participants, interventions, 
comparisons, outcomes, and study design (PICOS), as well as 
funding sources. Specifically, the recorded variables for each 
article included in the review were the following: author(s), year 
of publication, study design, sample size, eventual follow-up 
or control group, outcome measures, conclusions, limitations, 
quality score, and quality differentiation.
Risk of Bias in Individual Studies
Potential major confounding biases in the studies were 
ascertained at study level focusing on the following: 
measurement/diagnostic bias (e.g., lack of reliable diagnostic 
tools to make the diagnosis of TRS or TRP), confounding bias 
(e.g., lack of stratification and multivariate control for specific 
sociodemographic, vital, or clinical features), information 
(especially recall) bias, unrepresentativeness or inhomogeneity 
of the sample size or lack of control group (where applicable), 
FIGURE 2 | Meta-analysis of PANSS positive symptoms.
FIGURE 3 | Meta-analysis of PANSS negative symptoms.
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and selection by indication bias (nonrandom assignment of the 
exposure where applicable) (111).
Scoring and Ranking of the Studies
The present systematic review purposely encompassed a broad 
range of records and different types of study designs. To avoid an 
“apples and oranges” bias, we strived at stratifying the appraised 
results by discriminating between different quality levels. 
Specifically, observational case–control reports were appraised 
by means of the Newcastle–Ottawa Rating Scale (see Table 1) 
(118) and randomized controlled studies were appraised using 
the Jadad scale (see Appendix 1) (119).
Risk of Bias Across the Studies
Any eventual bias affecting cumulative evidence (e.g., publication 
bias, selective reporting within studies) was assessed through the 
study evaluation process and accounted in the discussion of the 
present manuscript.
RESULTS
The process of the literature search is shown in Figure 1. The 
search identified 42 references, of which 18 were RCT articles 
(see Table 2 for all the types of studies). Appendix 1 provides an 
overview of descriptive information about the 42 studies.
FIGURE 4 | Meta-analysis of PANSS total.
FIGURE 5 | Funnel plot of PANSS positive symptoms.
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Overall Number, Selected Number, and 
Typology of Psychotherapy Intervention
Only patients who had been stable on medication for a defined 
period (from 8 weeks to 6 months) were included in the studies. 
As reported in Table 3, CBT works were found in 32 trials: 25 
on individual and 7 on group CBT. Social skill training (SST) 
was studied in adjunction to CBT, and they were compared 
to supportive counseling (SC) in one trial (120). Works on 
family interventions (FI), psychosocial intervention (PI), 
psychoeducation (PE), key-person counseling (KC), cognitive 
remediation (CR), supportive counseling (SC), and supportive 
therapy (ST) were studied in comparison with CBT in 12 
CBT works. No studies with these interventions alone on TRP 
patients have been found. In one trial, CBT was compared to 
SC plus PE (121). Mindfulness was used in adjunction to CBT, 
acceptance-based intervention (ACT), and treatment of resistant 
command hallucinations (TORCH) in one study (122), while 
it was examined alone in another work (123). One study on 
multimodal individual psychotherapy, including individual 
CBT, was found (114). Two controlled trials that compared 
individual CBT to treatment as usual (TAU) have been collected 
(117, 124). One RCT that compared CBT to enriched TAU 
(125) has been found. The studies regarding other interventions 
alone were as follows: reasoning training (RT, n = 2) (112, 126), 
metacognitive therapy (MCT, n = 2) (127), cognitive therapy 
for command hallucinations (CTCH, n = 1) (128), art group 
FIGURE 6 | Funnel plot of PANSS negative symptoms.
FIGURE 7 | Funnel plot of PANSS total.
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therapy (n = 1) (129), occupational therapy (OT, n = 1) (130), 
and psychodynamic-interpersonal therapy (PIT, n = 1) (131).
Ten of the 42 studies regarded group therapy (116, 123, 129, 
132–138). They are shown in Table 5.
The CBT studies represented the majority of articles (32 out 
of 42). They were generally rigorous, as 22 out of 32 were of the 
RCT type, including 3 follow-up studies and 2 meta-analyses, 
while 10 studies included six trials with a control group. Only 
four CBT studies had no comparison group or control group. 
Some CBT researchers have used befriending (BF) (122, 139, 
140). An RCT study on BF in first episode psychosis has been 
found and reported in Appendix 2 (64). The mindfulness 
study used BF as a comparison group as well. The work on 
multimodal psychotherapy used a TAU control group. Of the 
remaining studies, 3 out of 9 included a control group: the brief 
RT was compared to the Attention Control Activity (141), OT 
was compared to clozapine alone (130), and the CTCH was 
compared to TAU (128).
Moreover, a meta-analysis (138) was focused on individual 
and group FI studies on schizophrenia patients who were both 
TR and not TR patients and included CBT works in TRS patients, 
who were accurately described.
For this reason, it has been incorporated in our work. A second 
phase of the same meta-analysis has been excluded, as it did not 
pertain to medication resistance (142). The dose of treatment was 
measured by the total number of sessions and was from 4 to 27, 
given throughout a period between 12 weeks and 24 months. In 
five studies, the number of sessions and the time of treatment 
were not specified.
Therapists and Blindness
Therapists were generally expert, except for one case (143). In two 
cases, the raters were trained and experienced nurses (140, 141). 
One study specifically on treatment resistance in early psychosis 
was found (144). Another study included early psychosis in 
a  heterogeneous group (93). Eighteen articles were trials with 
blind raters, while blindness could not be used in 21 works. Only 
one meta-analysis out of three was specifically focused on blind 
studies (145). The Cochrane review compared blind studies with 
nonblind studies (146).
Stage of Illness
The stage of illness (initial or chronic) was heterogeneous in 10 
studies, where the patients who were enrolled had different ages 
or very diverse duration of illness. In 11 articles, the duration of 
TABLE 1 | Newcastle-Ottawa Scale for assessing the quality of the included studies.
Newcastle–Ottawa Scale Case–Control Studies
 (http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp)
Author Year Selection—
case definition
Selection—
representativeness of 
the cases
Selection—
selection of 
controls
Selection—
definition of 
controls
Comparability 
of cases and 
controls
Exposure/
ascertainment 
of exposure
Ross et al. (112) 2009 * * * * * *
Cather et al. (113) 2005 * * * * * *
Temple, Ho. (124) 2004 * * * * ** *
Randal et al. (114) 2003 * * * * ** *
Durham et al. (115) 2003 * * * * * *
Levine et al. (116) 1998 * * * * * *
Garety et al. (117) 1994 * * * * * *
TABLE 2 | Study design of the included trials.
Type of study Number 
of studies
Number of studies with 
blind assessors
RCTs 18 14 blind studies
Randomized experimental trials 1 0 blind studies
Controlled clinical trials 5 2 blind studies 
Uncontrolled clinical trials 6 0 blind studies 
Case reports 3 0 blind studies
Pilot studies 2 0 blind studies
Follow-up studies 3 2 blind studies
Meta-analysis 3 2 (1 blind study + 1 blind vs. 
nonblind study)
Cochrane Intervention Review 1 1 blind vs. nonblind study
Total 42 21
TABLE 3 | Type of psychological intervention in the retrieved studies.
Psychological intervention Number 
of studies
Individual or group CBT vs. treatment as usual 17
and/or other nonspecific therapies
CBT, Psychosocial Intervention 2
CBT, Supportive Therapy 3
CBT, Psychoeducation (PE) 2
CBT, Supportive Counseling (SC) 1
CBT, SC + PE 1
CBT, Psychoeducation, SC 2
CBT, Family Intervention 1
CBT, Social Skill Training (SST), ST 1
CBT, ACT, TORCH, Mindfulness 1
CBT, Cognitive Remediation (CR) 1
Individual Multimodal Psychotherapy 1
Cognitive Therapy for Command Hallucinations 2
Reasoning Training 1
Mindfulness 1
Metacognitive Therapy 2
Art Group therapy 1
Occupational Therapy 1
Psychodynamic Interpersonal Therapy 1
Total 42
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illness was not specified. Twenty trials had a sample of chronic 
TRP patients. None of the found articles resulted in reporting 
the DUP.
Pharmacological Co-Treatment
In only two studies were there patients who were not on 
medication. In the first, there were 5 of 40 patients in an 
uncontrolled naturalistic study of CBT plus FI (147), while in 
the second there were 3 of 12 patients on individual CBT in a 
RCT (148). Remarkably, no study has proposed a psychological 
treatment as an alternative to medication in the whole sample. No 
study with regard to music therapy, specifically on medication-
resistant psychosis patients, has been found. However, other 18 
studies, which did not focus on TR patients and were not included 
in this research, have been collected in Appendix 2.
Clinical Outcome
Assessments used to measure improvement often differed between 
the various trials. Hence, we pooled study results either based or not 
based on statistics along with the authors' conclusion to compare 
them. See Table 4 for details on the number of works that had 
statistically significant outcomes. Articles reporting no improvement 
are also included in Table 4. No changes after treatment have been 
observed in only 2 studies out of 42. Those two trials were on CBT: 
one on CBT integrated with FI (147) and one on group CBT (132).
Symptoms and Clinical Domains
The symptomatology studied in the retrieved trials is mainly 
represented by the positive symptoms and, above all, the auditory 
hallucinations, especially in the CBT studies, while negative 
symptoms have been rarely evaluated. Ten studies out of 42 
reported a decrease of negative symptomatology (see Table 4). 
Efficacy on negative symptoms has been shown in three CBT 
trials and in ST, CR, CTCH, and OT. Art group therapy, MCT, 
and PIT trials have also reported a positive outcome on negative 
symptoms but without control group and not statistically 
evaluated (see Appendix 1 and Table 4). Affectivity has not 
been specifically evaluated, except for art group therapy and 
PIT. Clinical progress has also been observed in other areas, 
such as social functioning and personal care. Self-esteem and 
hopelessness have been evaluated, but their improvement has 
not been shown.
Studies with chronic patients affected by treatment 
resistance have shown that CBT could be effective, providing 
positive symptom reduction, which was considered equivalent 
to a “medium effect size.” A trend to effective treatment has 
been observed as well, in case series with psychosis onset, 
which was resistant to medication alone: almost three-quarters 
of patients achieved clinically significant improvement (144). 
However, results of CBT efficacy compared to other treatments 
in TRP are not homogeneous in all studies. For instance, 
when compared to other treatments, similar improvements 
to the CBT experimental group have been observed in other 
comparison groups, while a significant difference has been 
constantly observed only from TAU (132). In particular, in the 
Cochrane meta-analytical review on schizophrenia including 
TRS, psychosocial therapies have shown no clear difference 
from CBT for outcomes relevant to adverse effect/events, 
global mental state measures, and effects on positive or negative 
TABLE 4 | Improvements observed in the different psychological interventions, which were examined in the reviewed studies.
Psychological intervention on TRP patients Studies with 
statistically 
significant 
improvement
Studies with 
no statistically 
significant 
improvement
Studies with 
no different 
improvement 
between groups
Studies 
with no 
improvement
Studies with 
improvement 
specifically on negative 
symptoms
Individual CBT
Individual CBT vs. Befriending
Group CBT
Group CBT vs. Group ST
CBT vs. Psychosocial Intervention
CBT, Supportive Therapy
CBT vs. Psychoeducation
CBT vs. Supportive Counseling
CBT, Family Intervention
CBT, Social Skill Training vs. ST
CBT, (ACT, TORCH), Mindfulness vs. Befriending
CBT vs. Cognitive Remediation
Multimodal Psychotherapy
Reasoning Training
Cognitive Therapy for Command Hallucinations (CTCH)
Mindfulness
Metacognitive Therapy
Art Group Therapy
Occupational Therapy
Psychodynamic Interpersonal Therapy
8
1
3
1
0
0
0
2
1
0
0
0
1
1
1
0
2
0
1
0
2
0
0
0
0
0
0
0
0
0
0
0
0
1
0
1
0
1
0
1
0
1
0
1
1
1
2
3
0
1
1
1
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
2
1
0
0
0
0
1
0
0
0
1
0
0
1
1
0
1
0
1
1
Total 22 6 12 2 10
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symptoms (146). Moreover, the studies comparing CBT to another 
treatment, such as cognitive remediation (149), befriending (122, 
140), supportive therapy (115, 120, 134), psychoeducation (113, 
150), supportive counseling (121), or family intervention (138), 
have shown significant clinical improvement in all groups that 
were studied. Finally, a statistically significant major improvement 
in supportive therapy has also been observed (135). Two trials 
have shown a significant improvement in the CBT group when 
compared to other psychological interventions, such as befriending 
(139) or supportive counseling (151). Moreover, in two follow-up 
studies, CBT did not maintain the superiority to SC (152, 153). 
In particular, after 1 year from the end of treatment, CBT started 
to decline while SC improved, and this trend continued at 2-year-
follow-up. Finally, our results show that group therapy is related 
to significant improvement for all psychological interventions 
retrieved, except for family intervention (138), where single family 
treatment resulted better than the group family one. In six out of 
seven trials, group CBT presented the same improvement as the 
comparison group, showing the same results that were observed in 
the studies on individual CBT.
Meta-Analysis Result
The results obtained in our meta-analysis concerning the domain 
“POSITIVE SYMPTOMS” of the PANSS scale are as follows:
Fixed-effect meta-analysis: number of studies = 4; number of 
comparisons (k) = 4; total sample = 800 patients; SMD (standard 
mean difference) = 0.237 (C.I. = 0.097–0.376).
These preliminary results suggest that, on average, the PANSS 
score for positive symptoms was reduced by 23.7% more (with 
a margin between 9.7% and 37.6%) in patients who performed 
augmentation therapy with CBT compared to patients who 
received the usual therapy (TAU) (see Figure 2). Moreover, this 
reduction is statistically significant (p = 0.001).
Although the number of meta-analyzable studies is small, the 
heterogeneity index I2 is 0% (Figure 5).
The results obtained in our meta-analysis concerning the 
domain “NEGATIVE SYMPTOMS” of the PANSS scale are as 
follows:
Fixed-effect meta-analysis: no. of studies = 4; number of 
comparisons (k) = 4; total sample = 800 patients; SMD (standard 
mean difference) = 0.075 (C.I. = −0.063–0.214).
These preliminary results suggest that, on average, the PANSS 
score for negative symptoms was reduced by 7.5% more (with 
a margin between −6.3% and 21.4%) in patients performing 
augmentation therapy with CBT compared to patients receiving 
the usual therapy (TAU) (see Figure 3). However, this reduction 
is not statistically significant (p = 0.286).
Furthermore, it is noteworthy that the “lower limit” of the 
negative confidence interval (−6.3%) indicates how, at least in a 
small number of events, the CBT in augmentation to the usual 
treatment (TAU) could potentially induce even an effect opposite 
to the therapeutic one.
Although the number of meta-analyzable studies is small, the 
heterogeneity index I2 is also 0% in this case (Figure 6).
The results obtained in our meta-analysis concerning the 
“TOTAL Score” domain of the PANSS scale are as follows:
Random-effect meta-analysis: no. of studies = 5; number of 
comparisons (k) = 5; total sample = 843 patients; SMD (standard 
mean difference) = 0.220 (C.I. = 0.443–0.004).
These preliminary results suggest that, on average, the 
total score at the PANSS was reduced by 22% more (with a 
margin between 44.3% and −0.4%) in patients who performed 
augmentation therapy with CBT compared to patients who 
received the usual therapy (TAU) (see Figure 4). However, this 
result is not statistically significant (p = 0.054).
Moreover, in this case, the heterogeneity index I2 is equal 
to 46% and, being quite high, therefore indicates a poor 
homogeneity of the analyzed data (Figure 7).
DISCUSSION
Psychological Interventions
Psychological interventions in TRP patients have shown a 
therapeutic effect in 40 out of 42 selected studies. In particular, 
results demonstrate improvement in positive symptoms for 
CBT, as well as for other psychological interventions, albeit 
with different degrees. More specifically, CBT effects in 
selected studies were not statistically different respectively from 
psychosocial intervention (146), cognitive remediation (149), 
befriending (122, 140), supportive therapy (115, 120, 134, 135), 
psychoeducation (113, 150), supportive counseling (121), and 
family intervention (138).
CBT has been recognized as more efficient in persistent 
positive symptoms at follow-up. Supportive counseling (SC) 
was less effective than CBT at the 9-month follow-up, while 
it demonstrated the same efficacy as CBT at the following 
follow-up. Finally, the SC showed its superiority in some 
measures at 2 years follow-up (140, 153). It has been speculated 
that supportive counseling may enhance frequent and regular 
nonthreatening social interaction, which might have worked 
on self-esteem and helped patients to recuperate their social 
activity (16). Furthermore, metacognitive therapy has also 
shown significant improvements in both positive and negative 
symptoms compared to the baseline (but a control group was not 
provided) (127). Although art therapy is not strictly considered 
as a form psychotherapy, it has shown to lead to improvements 
in a short time in fields that are not easily measured by regular 
assessments, for example when considering interhuman 
relationship (129). Moreover, affectivity has not been specifically 
evaluated, except for art group therapy and psychodynamic 
interpersonal therapy (131), which were case series. In this work, 
clinical progress has also been observed in other areas such as 
social functioning, showing a marked reduction in the severe 
disturbances presented prior to treatment (131). Occupational 
therapy has been shown to give a statistically significant 
improvement compared to clozapine alone in the performance 
of the activity, in psychotic symptoms, social interaction, and 
personal care (130). Multimodal psychotherapy, reasoning 
training, and cognitive therapy for command hallucinations 
(CTCH) have also shown significant improvements compared 
to TAU (112, 114, 126, 128). The sample population targeted 
in the trials included different phases of the illness, showing 
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that an integrated treatment with psychological intervention 
and pharmacological treatment could be helpful at any point 
of the disease trajectory. On the contrary, no data on the use of 
psychological intervention alone on TRP patients are currently 
available.
Few methodological issues need to be considered, such as 
the type of intervention, characteristics of the sample, including 
age of patients as well as stage of the illness, and duration of 
the treatment. With regard to the type of intervention, it 
has already been observed that all psychological therapies, 
including befriending and supportive therapy, may have a 
clinically relevant impact, and statistically significant results 
are reported in more than half of the trials included in this 
review (22 out of 42, see Table 4).
A controversial aspect of psychotherapeutic interventions 
in TRP is represented by the fact that psychological 
interventions, including CBT, have an effect mainly on positive 
symptoms while they seem to be less clearly effective on other 
main aspects, such as negative and cognitive symptoms. 
Eighteen CBT trials have shown that CBT, in adjunction to 
antipsychotics, could produce better outcomes on a variety 
of measures than medication alone, but target treatment was 
mainly represented by positive symptoms. In fact, negative 
symptoms are generally left aside and remained prevalently 
persistent in the majority of studies. In some trials, negative 
symptoms have not even been evaluated. In summary, 10 
studies out of 42 reported a significant reduction of negative 
symptomatology: 3 on CBT, 1 on CR, 1 on MCT, 1 on CTCH, 
2 on occupational therapy, 1 on art group therapy, and 1 on 
psychodynamic interpersonal therapy (see Table 4). These 
evidence are also compatible with the result of a recent meta-
analysis on psychological treatments of negative symptoms in 
a population of psychotic patients that were not specifically 
resistant to treatment (154). In particular, improvement in 
negative symptoms has been observed after CBT intervention 
in patients who were at any stage of the disease. This 
amelioration has resulted in 59% of the studies when CBT was 
compared to TAU, while none of the analyzed studies suggested 
a benefit of CBT if compared to active controls. Moreover, 
another recent meta-analysis for a total of 4,068 patients who 
were on average moderately ill at baseline has confirmed the 
efficacy of CBT on positive symptomatology (155). A recent 
systematic review has newly reported that CR can also have 
beneficial effects on negative symptoms, compared to TAU 
and TAU plus active control in schizophrenia patients who 
were not treatment resistant (68).
Additional researches are needed in order to test “self-
disturbance” (156, 157). Consequently, it would be necessary 
“to tailor” psychological treatment aimed at this symptom. 
Since the “hyperreflexive attitude” is typical in self-disturbance 
and in nonaffective psychosis, CBT might not be the most 
suited psychological intervention on these patients. This is 
due to the fact that an important feature of this therapeutic 
approach is the encouragement of “thinking about thinking” 
(14, 158), which is what the patients already do repeatedly in a 
pathological fashion (159).
It has been observed that brain dysfunctions, for example, 
dopaminergic supersensitivity, could be secondary to 
psychological events (74, 160). Furthermore, studies on brain 
receptor availability after psychotherapy treatments (both 
CBT and psychodynamic psychotherapy) have shown that 
a neurobiological alteration can be modifiable or reversible 
thanks to psychological interventions (161–164). Further steps 
in augmentation with psychological therapy of TRP seem to 
be focusing on the total symptomatology, including positive, 
negative, and self-disturbance. Considering that symptoms 
are part of unitary and complex psychopathology, acting on 
one aspect could be partial. On the other hand, publications 
on psychodynamic psychotherapy, which is focused on 
unconscious dimension, are poorly available; only one paper 
referring specifically to TRP patients has been found in this 
review (131).
Other critical points are as follows: the characteristics of 
the sample, age of patients, stage of illness, and duration of the 
treatment. Some gaps have to be highlighted. Firstly, a marked 
heterogeneity of the selected sample has been observed in 10 
trials, while 11 studies did not take it into account. For instance, 
patients at different ages or at difference stages of illness (early 
stage, acute or chronic phase) were located in the same group. 
For example, 18-year-old patients were in the same group as 
40-, 50-, and 60-year-old patients: considering the different 
psychopathological conditions and the long-term effects of the 
illness (165), patients respond differently.
Furthermore, it has been observed that factors associated 
with better outcome include a shorter duration of illness and 
less severe symptom at pretreatment (151, 166). In addition, 
in the acute phase of psychosis, CBT can produce durable and 
substantial clinical benefits (165). Concerning the detailed 
diagnosis of TR, if two different types of TRP or TRS (at the 
early and at the chronic stage of illness) have been identified, 
they should be studied separately and not in the same sample. 
Secondly, in the majority of studies, the duration of the 
treatment ranged from 4 weeks to 9 months. Only 2 studies 
out of 42 (114, 138) used a duration of treatment up to 21–24 
months, and in one study (147), the length of intervention 
was 12 months. In two studies, therapy was administered in 
one single session (112, 126), and in four trials, duration of 
treatment was not even specified. A significant recovery could 
not be expected during a 2-month treatment period, when 
patients are markedly ill and/or chronic with persistent and 
expressed negative symptoms of schizophrenia (129). This is 
supported by the observations of an increased effect over time of 
CBT on mental state (140). For instance, in the selected articles, 
a longer duration of treatment can generally show better results 
on negative symptoms. On the other hand, recent publications 
on the comparison between short- and long-term psychotherapy 
have shown contrasting results (167, 168). However, these works 
were referred to nonpsychotic patients. A short-term duration 
is insufficient for psychotic onset patients, who need to be 
treated longer, considering guidelines (169). Finally, according 
to our results, as reported in Table 5, group therapy should also 
be encouraged, as it is generally well supported by evidence in 
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improving persistent positive symptom in both CBT and other 
psychological interventions.
Exploratory Meta-Analysis of Cognitive 
Behavioral Therapy Interventions
The results obtained from our meta-analytical extraction have 
confirmed that cognitive–behavioral psychotherapy is very 
effective particularly in the treatment of positive symptoms in 
TRS and/or TRP patients. This result is in line with what has 
already been found in other studies in the literature. The same 
efficacy was not found in the treatment of negative symptoms 
while it was only partial in achieving an improvement in the 
total scores of patients evaluated in the PANSS. We have also 
found that CBT in augmentation with the usual treatment 
(TAU) works well in the initial stages and then gradually loses 
effectiveness (170). In this regard, we can hypothesize that 
schizophrenia worsens over time, making treatment with CBT 
more difficult and therefore less effective; moreover, it could 
happen that, in the initial stages of treatment, there is a sort of 
“feeling of well-being” that does not necessarily coincide with a 
real clinical improvement. However, there are very few studies 
with a sufficiently long follow-up to clarify these hypotheses. As 
regards the low incisiveness of CBT on negative symptoms, we 
can hypothesize that patients with more pronounced negative 
symptoms and therefore with affective dullness and social 
withdrawal are less suitable for this type of psychotherapeutic 
approach or that these symptoms require a longer duration of 
treatment to be effectively affected. Moreover, given that the few 
studies in the literature with a longer follow-up have shown an 
efficacy also on the negative symptoms, we can hypothesize that 
the patients followed for a longer period may have benefited 
from therapeutic adjustments over time as well as from the 
CBT. The limits of these results are in some way superimposable 
to those already listed above about the systematic review on 
the same topic. In addition to what has already been said, the 
incompleteness and the partiality of the data at our disposal are 
worth noting, as, for example, not all the articles indicated the 
dropout rates accurately, or at what time of the treatment they 
occurred, or which group they belonged to (cases or controls).
CONCLUSIONS AND FUTURE 
RESEARCH DIRECTIONS
Psychotherapy should be considered a potential relevant 
therapeutic strategy in adjunction to medication in TRP 
patients. An intervention on psychosis that does not consider 
an integrative approach could miss a potential effective 
component of the treatment. However, few questions need to 
be addressed in the future in order to better understand the 
role of psychotherapy in TRP. Firstly, it would be appropriate 
to start with large-scale multicenter, controlled studies based 
on psychotherapeutic approaches (i.e., CBT) that were shown 
to be effective in smaller studies and to include patients with 
homogeneous domains of symptoms, duration and doses 
of antipsychotic treatment, as well as duration of illness. 
Secondly, a longer time of treatment should be conceived in 
such studies in order to get an adequate signal of the response. 
Finally, even if challenging, an important issue is to consider 
the inclusion of biological markers (i.e., functional imaging) 
before and after the introduction of the psychotherapeutic 
augmentation or of the substitution psychotherapy. Moreover, 
future studies need to adopt reliable operational outcome 
measures for non-CBT studies to allow quantitative extraction 
of information and reliable comparison of efficacy measures 
for psychological interventions other than cognitive therapy 
that are currently almost invariably not assessed in a 
controlled, RCT fashion.
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TABLE 5 | Comparison between different group psychotherapies.
Author/type of study Efficacy Comparison between different group therapy Type of therapy
Mandić-Gajić G (129) Case reports Yes No Group art therapy
Jacobsen et al. (123) Uncontrolled study Yes No Group Mindfulness
Penn et al. (135) RCT Yes Yes, improvement in ST at posttreatment and in both groups 
at follow-up
Group CBT, Group ST
Johnson et al. (134) RCT Yes Yes, improvement in both groups with no significant difference Group CBT, Group ST
Barrowclough et al. (132) RCT No No Group CBT
Wykes et al. (137) RCT Yes No Group CBT
Pinkham et al. (136) Pilot study Yes No Group CBT
Pilling et al. (138) Meta-analysis (part of the study 
including heterogeneous population: both TRP and 
not TRP)
No No. No comparison has been made with single FI.
Single FI became more efficient than group FI (not statistically 
significant)
Group FI (vs. Individual CBT)
Chadwick et al. (133) Uncontrolled study Yes No Group CBT
Levine et al. (116) Controlled trial Yes No Group CBT
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